IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells

Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine

(2015) Richard J. Honeywell et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin

(2015) Saman Maleki Vareki et al.   Oncotarget

The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress

(2013) F. Sahm et al.   CANCER RESEARCH

Pemetrexed for the treatment of non-small cell lung cancer

(2013) Carlo Genova et al.   EXPERT OPINION ON PHARMACOTHERAPY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Uracil-DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed

(2013) L. D. Weeks et al.   MOLECULAR CANCER THERAPEUTICS

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

(2013) Ben C. Creelan et al.   OncoImmunology

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

(2012) Michael S. Gordon et al.   INVESTIGATIONAL NEW DRUGS

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair

(2012) A D Bulgar et al.   Cell Death & Disease

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors

(2011) Heba A Alshaker et al.   Cancer Cell International

Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer

(2011) Sung Hoon Sim et al.   CANCER SCIENCE

Thymidylate synthase inhibitors for non-small cell lung cancer

(2011) Elena Galvani et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Combining Small Interfering RNAs Targeting Thymidylate Synthase and Thymidine Kinase 1 or 2 Sensitizes Human Tumor Cells to 5-Fluorodeoxyuridine and Pemetrexed

(2011) C. Di Cresce et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

(2011) Maria T Pallotta et al.   NATURE IMMUNOLOGY

The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways

(2010) Riekelt H. Houtkooper et al.   ENDOCRINE REVIEWS

Inhibition of Nicotinamide Phosphoribosyltransferase

(2010) Maria Pittelli et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer

(2009) Aaron S Mansfield et al.   BMC CANCER

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

(2009) Anne von Heideman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

(2009) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model

(2008) N. Yoshida et al.   CLINICAL CANCER RESEARCH

Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

(2008) Ke Pan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY